EFFRITE
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- méthylprednisolone
Compared with
- Rituximab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Primary end point: Osteopontine level in CSF at day 4.
Blood or spinal fluid markers
Other measures (1)
Multiple secondary end points will be used:
Who could take part
Progressive MS
Inclusion: Age ≥45 years, male or female ; Exclusion: Relapsing-remitting phase of MS;
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Our goal is to study the kinetics of action of a single dose of intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets.
Papers
Loading reviews and guidelines…
Related trials
- GAVOTTE
Phase 3 · Running, not recruiting
Missed its main goal
- SCALA
Phase 1 · Completed
Result in a paper, not read yet
- EFFRITE
Phase 2 · Completed
Missed its main goal
- COMTiMS
Phase 2 · Completed
Result in a paper, not read yet
- EPO-ProgMS
Phase 2 · Status unknown
No result found
- EPO-ProgMS
Phase 2 · Completed
History
Started
Mar 2018
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error